Table 1.
Anti-HBs Titer ≥ 10 mIU/ml before and after Booster Dose.
| Authors | Country of Study | Study Design | Year of Study | Age at Follow up (Years) | Study Population | Patients with anti-HBS ≥ 10 mIU/ml | Anti-HBS antibody Titer After Boosting | Vaccine Type | Dosage of Vaccine | Vaccination Schedule 1 s 2nd 3rd | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bruce et al. | Alaska | Prospective Cohort | 2011 | 30 | 243 | 51% | 88% | Plasma Derived | Standard | Vaccinated at 06 months age. | ||
| Wu et al. | China | Randomized placebo controlled cohort | 2010 | 23 | 126 | 48.1% | 84% | Plasma Derived | Standard | 00 | 01 | 06 |
| Poovorawan et al. | Thailand | Cohort Study | 2009 | 20 | 109 | 60.5% | 83.9% | Recombinant | Standard | 00 | 01/02 | 12 |
| Al-Ghamdi et al. | Saudi Arabia | Cross Sectional Cohort Study | 2012 | 20 | 238 | 58.8% | Not Specified | Standard | ||||
| Su et al. | Taiwan | Cross Sectional Study | 2012 | 18 | 1734 | 35.9% | 95% | Plasma Derived | Standard | 01 | 02 | 12 |
| Al Faleh et al. | Saudi Arabia | Cross Sectional Study | 2008 | 18 | 1355 | 38.0% | Not Specified | Recombinant | Standard | 00 | 01 | 06 |
| Spada et al. | Italy | Follow up Study | 2010 | 17 | 571 | 72.9% | Not Specified | Standard | ||||
| Middleman et al. | U.S.A | Cross Sectional Study | 2014 | 16–19 | 420 | 24.0% | 92% | Recombinant | Standard | 00 | 01 | 12 |
| Avidoca et al. | Slovakia | Longitudinal Study | 2010 | 10–11 | 31 | 48.4% | 96% | Standard | 03 | 05 | 12 | |
| Gold et al. | Israel | Cross Sectional Study | 2000 | 08 | 122 | 77.1% | Not Specified | Recombinant | Standard | 00 | 01 | 06 |
| Tsega et al. | Ethiopia | Longitudinal Study | 2010 | 05 | 314 | 89% | Not Specified | Recombinant | Standard | 00 | 01 | 06 |
| Amini et al. | Iran | Longitudinal Study | 1999 | 02 | 542 | 97% (Children) 82% (Adults) | Not Specified | Recombinant | Standard | 00 | 01 | 06 |